Clinical Predictors of Response to Tocilizumab: A Retrospective Multicenter Study
TURKISH THORACIC JOURNAL, cilt.23, sa.3, ss.225-230, 2022 (ESCI, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 23 Sayı: 3
- Basım Tarihi: 2022
- Doi Numarası: 10.5152/turkthoracj.2022.21179
- Dergi Adı: TURKISH THORACIC JOURNAL
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
- Sayfa Sayıları: ss.225-230
- Anahtar Kelimeler: Tocilizumab, COVID-19, mortality, biomarkers, CALL score
- Dokuz Eylül Üniversitesi Adresli: Evet
Özet
OBJECTIVE: A substantial number of patients with coronavirus disease-2019 (COVID-19) demonstrate severe infection. Cytokine storm is an underlying condition that worsens clinical outcomes. As an interleukin-6 receptor antagonist, tocilizumab is a promising treatment option for COVID-19. This study aimed to evaluate the clinical predictors of mortality for critically ill COVID-19 patients receiving tocilizumab therapy.